Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Full Dose Strength Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets

NCT01057966
View directory record Official record
Conditions
Vision
Interventions
ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength), ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength), ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)
Dietary Supplement
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 3, 2026, 6:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Project 4A: Inspiratory Muscle Training and Diaphragm Strength

NCT02367170
View directory record Official record
Conditions
Sepsis
Interventions
Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples
Procedure · Drug · Device + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 3, 2026, 6:56 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans

NCT04596644
View directory record Official record
Conditions
Cannabis, Pain, Tolerance, Hyperalgesia
Interventions
Active Cannabis, Placebo Cannabis
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 3, 2026, 6:56 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

FIH Lead-in Study of YASO GEL Followed by a Phase 1 Randomized, Double-blind Study to Assess Safety and Pharmacokinetics of YASO GEL

NCT07281404
View directory record Official record
Conditions
Early-phase Safety and PK Study of a Vaginal Gel
Interventions
YASO GEL, Placebo gel
Drug
Lead sponsor
Yaso Therapeutics Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Repeated Cannabis Administration on Experimental Pain and Abuse Liability

NCT04576507
View directory record Official record
Conditions
Cannabis, Pain, Tolerance, Hyperalgesia
Interventions
Active Cannabis, Placebo Cannabis
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

NCT03695939
View directory record Official record
Conditions
Deep Full-thickness Burn Injury (Disorder)
Interventions
realSKIN (skin xenotransplant), Human Cadaver Allograft
Biological
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

NCT01922050
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X, LEO 43204 Formulation 1 Dose Y, LEO 43204 Formulation 2 Dose XX, LEO 43204 Formulation 2 Dose YY, Placebo Formulation 1, Placebo Formulation 2
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Lomita, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

NCT07225413
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules
Dietary Supplement
Lead sponsor
Jacksonville State University
Other
Eligibility
18 Weeks to 40 Weeks
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

NCT01750918
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 3, 2026, 6:56 PM EDT
Withdrawn Phase 2 Interventional

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

NCT01104844
View directory record Official record
Conditions
Dental Pain
Interventions
Full Dose Strength, Quarter dose strength, Half dose strength, Acetaminophen standard dose, Ibuprofen low dose, Ibuprofen high dose, Placebo
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities

NCT05492240
View directory record Official record
Conditions
Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Interventions
i-STRONGER, Usual Care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 120 Years
Enrollment
4,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

NCT00761774
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
25
States / cities
Phoenix, Arizona • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Onset of Action of a Fast Release Aspirin

NCT01420094
View directory record Official record
Conditions
Healthy Subjects
Interventions
Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 3, 2026, 6:56 PM EDT
Terminated No phase listed Observational

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

NCT01532232
View directory record Official record
Conditions
Breast Cancer, Tobacco Dependence
Interventions
placebo, varenicline
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

NCT00252174
View directory record Official record
Conditions
Anxiety Disorder, Cancer
Interventions
Stage 1 Active Methylenedioxymethamphetamine, Stage 1 Low dose Methylenedioxymethamphetamine, Psychotherapy, Stage 2 Active Methylenedioxymethamphetamine
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 3, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty

NCT06234631
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis, Knee
Interventions
Epidiolex oral solution, Placebo
Drug · Other
Lead sponsor
Chad Brummett
Other
Eligibility
18 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 6:56 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

NCT06851754
View directory record Official record
Conditions
Premature Ovarian Insufficiency
Interventions
Progesterone, Estrogen Patch
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
11 Years to 19 Years · Female only
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 3, 2026, 6:56 PM EDT